eMedicine Specialties > Urology > Infections and Related Inflammatory Conditions

Prostatitis, Bacterial

Author: Joe D Mobley III, MD, MPH, Chief Resident Physician, Department of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine/University of Tennessee Medical Center
Coauthor(s): Edward David Kim, MD, FACS, Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center
Contributor Information and Disclosures

Updated: Oct 8, 2009

Introduction

Background

Chronic bacterial prostatitis represents an infection of the prostate gland. By definition, this condition is characterized by bacterial growth in culture of the expressed prostatic fluid, semen, or postmassage urine specimen. The expressed prostatic secretion (EPS) usually contains more than 10 white blood cells (WBCs) per high-power field (HPF) and macrophages.

Bacterial prostatitis. Expressed prostatic fluid ...

Bacterial prostatitis. Expressed prostatic fluid contains more than 10 white blood cells per high-power field, indicating prostatitis.

Bacterial prostatitis. Expressed prostatic fluid ...

Bacterial prostatitis. Expressed prostatic fluid contains more than 10 white blood cells per high-power field, indicating prostatitis.


The hallmark of chronic bacterial prostatitis is the occurrence of relapsing urinary tract infections, usually involving the same pathogen. Chronic bacterial prostatitis is often confused with nonbacterial prostatitis, chronic pelvic pain syndrome (CPPS), and prostatodynia.

Pathophysiology

The prostate gland is an accessory sex gland, providing approximately 15% of the ejaculate. The base of the prostate abuts the bladder neck, while the apex is in continuity with the membranous urethra, resting on the urogenital diaphragm.

The adult prostate weighs approximately 20 g but may grow dramatically with age (see Prostate Hyperplasia, Benign). The approximate dimensions are 4.4 cm transversely at the base, 3.4 cm in length, and 2.6 cm in anteroposterior diameter. Antibacterial factors within the prostate, such as zinc, help to prevent infection.

Frequency

United States

Prostatitis accounts for approximately 2 million annual visits. Twenty-five percent of all men evaluated for urologic problems in the United States are estimated to have symptoms of prostatitis. Approximately 50% of men experience symptoms of prostatitis at some time in their life. However, less than 5-10% of men with symptoms of prostatitis have bacterial prostatitis. Evaluation for these symptoms makes up approximately 8% of all urology visits.

International

Worldwide, 8 million prostatitis-related visits are reported annually.

Mortality/Morbidity

  • Chronic bacterial prostatitis is not associated with mortality. However, acute bacterial prostatitis (discussed in Acute Bacterial Prostatitis and Prostatic Abscess) represents a potentially lethal process if untreated.
  • The morbidity associated with chronic bacterial prostatitis is related to its relapsing nature. Chronic bacterial prostatitis may be difficult to eradicate because of the persistence of bacteria within the prostatic acini. Factors that contribute to bacterial persistence include (1) a poor ductal drainage system within the prostate, which can lead to congestion of prostatic secretions, and (2) the tendency for urine to reflux into the prostatic ducts, which may cause irritation and inflammation.

Race

No racial predilections have been identified.

Sex

Bacterial prostatitis affects in males.

Age

Chronic bacterial prostatitis typically affects men aged 40-70 years. Benign prostatic hyperplasia typically affects the same age group.

Clinical

History

Relapsing urinary tract infections, interspersed with asymptomatic periods, are common in persons with chronic bacterial prostatitis. Although some men are diagnosed because of asymptomatic bacteriuria, most have varying degrees of irritative voiding symptoms, such as dysuria, frequency, and urgency.

In addition, some patients report feelings of a vague discomfort in the pelvis and perineum. Fevers and chills are uncommon. Rectal palpation of the prostate is not painful and produces no specific findings. Prostatic fluid and postmassage urine cultures, which should be obtained for precise diagnosis, demonstrate bacterial growth.

  • Characteristics of chronic bacterial prostatitis include the following:
    • Chronic bacterial prostatitis is the most common cause of relapsing urinary tract infection in males.
    • Asymptomatic periods are interspersed between episodes of recurrent bacteriuria.
    • Obstructive or irritative voiding symptoms may occur.
    • Vague discomfort in pelvis, perineum, lower abdomen, back and testicles is reported.
    • Physical findings on palpation are often unremarkable.
    • EPS, postmassage urine culture, or semen culture must be obtained for a precise diagnosis.
  • Symptoms of prostatitis include the following:
    • Genitourinary pain
    • Dysuria and hematospermia
    • Clear urethral discharge
    • Recurrent urinary tract infection
  • The spectrum of organisms grown in culture in chronic bacterial prostatitis is essentially the same as in acute bacterial prostatitis. Most infections are caused by a single pathogen, but a polymicrobial infection is not unusual. Obligate anaerobic bacteria rarely cause prostatic infection.
  • Localization cultures do not need to demonstrate greater than 100,000 colony-forming units (CFU) per milliliter to establish the diagnosis. Instead, the presence of a greater than 10-fold bacterial growth in the EPS or the third midstream bladder specimen (VB3) compared with the first voided bladder specimen (VB1) and the second midstream bladder specimen (VB2) is important.
  • Common bacterial pathogens, predominated by gram-negative rods, include the following:  
    • Escherichia coli (80%)

      Urine culture with greater than 100,000 colony-fo...

      Urine culture with greater than 100,000 colony-forming units (CFU) of Escherichia coli, the most common pathogen in acute and chronic prostatitis. Chronic bacterial prostatitis must be confirmed and diagnosed using a urine culture.

      Urine culture with greater than 100,000 colony-fo...

      Urine culture with greater than 100,000 colony-forming units (CFU) of Escherichia coli, the most common pathogen in acute and chronic prostatitis. Chronic bacterial prostatitis must be confirmed and diagnosed using a urine culture.

    • Klebsiella species
    • Enterobacter species
    • Proteus enterococci species
    • Pseudomonas species
    • Staphylococcus species

Physical

The physical examination findings, including the findings on prostate examination via digital rectal examination, are typically normal.

  • The prostate may have areas of firmness related to chronic inflammation. While prostatic calculi are associated with a higher risk of chronic bacterial prostatitis, they are rarely palpable on prostate examination because of their location, which is typically deep within the prostate gland.
  • In contrast, acute bacterial prostatitis is characterized by a very tender, warm, swollen, firm gland. When acute bacterial prostatitis is suspected, prostate massage should be avoided because of the risk of causing bacteremia.
  • While chronic bacterial prostatitis may be associated with symptoms of perineal, scrotal, and low back discomfort, the physical examination findings are typically normal.

Causes

The actual routes of prostatic infection are unknown in most cases, but various etiologies may be found. Ascending urethral infection is a known route because of the frequency of previous gonococcal prostatitis, as well as the finding of identical organisms in prostatic fluid and vaginal culture in many couples. Intraprostatic urinary reflux has been demonstrated in human cadavers and may play a role.

  • Routes of infection include the following:
    • Ascending urethral infection
    • Reflux of infected urine into prostatic ducts
    • Migration of rectal bacteria via direct extension or lymphogenous spread
    • Hematogenous infection
  • The relapsing nature of bacterial prostatitis is due in part to the ductal anatomy of the prostate’s peripheral zone, which prevents dependent drainage of secretions. This can lead to congestion and thickening of prostatic secretions and provides a nidus for recurrent infections. Ductal fibrosis and prostatic calculi, if present, further inhibit the drainage of secretions.
  • E coli infection accounts for 80% of cases of chronic bacterial prostatitis. The other members of the Enterobacteriaceae family, Klebsiella species, Pseudomonas aeruginosa, and Proteus species are also known pathogens. Chlamydia trachomatis has been implicated as a cause of chronic bacterial prostatitis.1 However, this organism is unlikely to play a major role in the etiology of chronic bacterial prostatitis.
  • The role of the gram-positive organisms Staphylococcus epidermitis and Staphylococcus saprophyticus is controversial. These organisms typically colonize the anterior urethra and likely represent contamination when positive in a culture specimen. Only patients in whom a second culture result is positive should receive antibiotic treatment.
  • Prostatic calculi, although an unspecific finding, often develop in men with chronic bacterial prostatitis; prostatic calculi may serve as a nidus for recurrent infection. A newly described entity termed nanobacteria is thought to play a significant role in urologic stone disease, including prostatic calculi.2 Nanobacteria may play a role in the chronic nature of this condition. Studies are currently underway to further delineate the role of these organisms in chronic bacterial prostatitis.
  • The National Institutes of Health (NIH) classification of prostatitis: Based on specific etiologies, the NIH classified the various forms of prostatitis in 1995.3 The most common type of prostatitis is type III, the chronic pelvic pain syndrome (CPPS) category.
    • Type I - Acute bacterial prostatitis
      • Well-defined infectious disease of the lower urinary tract
      • Bacterial cause, most commonly E coli infection
      • Frequently presents with bacteremia
    • Type II - Chronic bacterial prostatitis (focus of this article)
    • Type III - Chronic abacterial prostatitis (inflammatory CPPS and noninflammatory CPPS)
      • Most common prostatitis (90% of cases)
      • Nonbacterial
      • Diagnosed based on EPS findings, clinical findings, and culture results
      • Empiric trial of antimicrobials usually warranted (fluoroquinolone or trimethoprim-sulfamethoxazole [TMP-SMZ])
    • Type IV - Asymptomatic inflammatory prostatitis
      • Often diagnosed based on results of biopsies, surgical specimens, or semen analysis obtained for other reasons
      • No treatment warranted
      • Biopsy typically indicated because of elevated prostate-specific antigen (PSA) level

More on Prostatitis, Bacterial

Overview: Prostatitis, Bacterial
Differential Diagnoses & Workup: Prostatitis, Bacterial
Treatment & Medication: Prostatitis, Bacterial
Follow-up: Prostatitis, Bacterial
Multimedia: Prostatitis, Bacterial
References
Further Reading

References

  1. Weidner W, Diemer T, Huwe P, Rainer H, Ludwig M. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents. Jun 2002;19(6):466-70. [Medline].

  2. Wood HM, Shoskes DA. The role of nanobacteria in urologic disease. World J Urol. Feb 2006;24(1):51-4. [Medline].

  3. NIH Summary Statement. NIDDK Workshop on Chronic Prostatitis, Bethesda, Md. December 1995.

  4. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. Mar 1968;5(5):492-518. [Medline].

  5. Magri V, Wagenlehner FM, Montanari E, Marras E, Orlandi V, Restelli A, et al. Semen analysis in chronic bacterial prostatitis: diagnostic and therapeutic implications. Asian J Androl. Jul 2009;11(4):461-77. [Medline].

  6. Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol. Mar 1998;159(3):883-7. [Medline].

  7. Paulson DF, White RD. Trimethoprium-sulfamethoxazole and minocycline- hydrochloride in the treatment of culture-proved bacterial prostatitis. J Urol. Aug 1978;120(2):184-5. [Medline].

  8. Sohn DW, Han CH, Jung YS, Kim SI, Kim SW, Cho YH. Anti-inflammatory and antimicrobial effects of garlic and synergistic effect between garlic and ciprofloxacin in a chronic bacterial prostatitis rat model. Int J Antimicrob Agents. Sep 2009;34(3):215-9. [Medline].

  9. Meares ET. Chronic bacterial prostatitis: role of transurethral prostatectomy (TURP) in therapy. In: Schmiedt E, Alken JE, Bauer HW, eds. Therapy of prostatitis. Munich, Germany: Zuckerschwerdt Verlag; 1986:193-197.

  10. Murphy AB, Macejko A, Taylor A, Nadler RB. Chronic prostatitis: management strategies. Drugs. 2009;69(1):71-84. [Medline].

  11. Plomp TA, Baert L, Maes RA. Treatment of recurrent chronic bacterial prostatitis by local injection of thiamphenicol into prostate. Urology. Jun 1980;15(6):542-7. [Medline].

  12. Jiménez-Cruz JF, Tormo FB, Gómez JG. Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol. May 1988;139(5):967-70. [Medline].

  13. Magri V, Perletti G, Montanari E, Marras E, Chiaffarino F, Parazzini F. Chronic prostatitis and erectile dysfunction: results from a cross-sectional study. Arch Ital Urol Androl. Dec 2008;80(4):172-5. [Medline].

  14. Weidner W, Schiefer HG, Brahler E. Refractory chronic bacterial prostatitis: a re-evaluation of ciprofloxacin treatment after a median followup of 30 months. J Urol. Aug 1991;146(2):350-2. [Medline].

  15. Bjerklund Johansen TE, Grüneberg RN, Guibert J, Hofstetter A, Lobel B, Naber KG, et al. The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. Dec 1998;34(6):457-66. [Medline].

  16. Budía A, Luis Palmero J, Broseta E, Tejadillos S, Benedicto A, Queipo JA, et al. Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method. Scand J Urol Nephrol. 2006;40(4):326-31. [Medline].

  17. Bundrick W, Heron SP, Ray P, Schiff WM, Tennenberg AM, Wiesinger BA, et al. Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study. Urology. Sep 2003;62(3):537-41. [Medline].

  18. Habermacher GM, Chason JT, Schaeffer AJ. Prostatitis/chronic pelvic pain syndrome. Annu Rev Med. 2006;57:195-206. [Medline].

  19. Kaplan SA, Santarosa RP, D'Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, et al. Pseudodyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic nonbacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol. Jun 1997;157(6):2234-7. [Medline].

  20. Krieger JN. Prostatitis revisited: new definitions, new approaches. Infect Dis Clin North Am. Jun 2003;17(2):395-409. [Medline].

  21. Kurzer E, Kaplan S. Cost effectiveness model comparing trimethoprim sulfamethoxazole and ciprofloxacin for the treatment of chronic bacterial prostatitis. Eur Urol. Aug 2002;42(2):163-6. [Medline].

  22. Leigh DA. Prostatitis--an increasing clinical problem for diagnosis and management. J Antimicrob Chemother. Jul 1993;32 Suppl A:1-9. [Medline].

  23. McGuire EJ, Lytton B. Bacterial prostatitis: treatment with trimethoprim-sulfamethoxazole. Urology. May 1976;7(5):499-500. [Medline].

  24. Meares EM Jr. Prostatitis. Med Clin North Am. Mar 1991;75(2):405-24. [Medline].

  25. Moon TD. Questionnaire survey of urologists and primary care physicians' diagnostic and treatment practices for prostatitis. Urology. Oct 1997;50(4):543-7. [Medline].

  26. Pansadoro V, Emiliozzi P, Defidio L, Scarpone P, Sabatini G, Brisciani A, et al. Prostate-specific antigen and prostatitis in men under fifty. Eur Urol. 1996;30(1):24-7. [Medline].

  27. Schaeffer AJ, Wendel EF, Dunn JK, Grayhack JT. Prevalence and significance of prostatic inflammation. J Urol. Feb 1981;125(2):215-9. [Medline].

  28. Shoskes DA, Katz E. Multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. Jul 2005;6(4):296-9. [Medline].

  29. Shoskes DA, Thomas KD, Gomez E. Anti-nanobacterial therapy for men with chronic prostatitis/chronic pelvic pain syndrome and prostatic stones: preliminary experience. J Urol. Feb 2005;173(2):474-7. [Medline].

  30. Stamey TA, Meares EM Jr, Winningham DG. Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid. J Urol. Feb 1970;103(2):187-94. [Medline].

  31. Wagenlehner FM, Naber KG. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. Curr Urol Rep. Aug 2004;5(4):309-16. [Medline].

  32. Wiygul RD. Prostatitis: epidemiology of inflammation. Curr Urol Rep. Jul 2005;6(4):282-9. [Medline].

  33. Wright ET, Chmiel JS, Grayhack JT, Schaeffer AJ. Prostatic fluid inflammation in prostatitis. J Urol. Dec 1994;152(6 Pt 2):2300-3. [Medline].

Further Reading

For additional information, see Medscape’s Prostatitis Resource Center.

Keywords

chronic urinary tract infections, UTI, acute bacterial prostatitis, chronic bacterial prostatitis, chronic abacterial prostatitis, asymptomatic inflammatory prostatitis, nonbacterial prostatitis, chronic pelvic pain syndrome, CPPS, prostatodynia, asymptomatic bacteriuria, dysuria, ascending urethral infection, gonococcal prostatitis, intraprostatic urinary reflux

Contributor Information and Disclosures

Author

Joe D Mobley III, MD, MPH, Chief Resident Physician, Department of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine/University of Tennessee Medical Center
Joe D Mobley III, MD, MPH is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, Endourological Society, and Tennessee Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Edward David Kim, MD, FACS, Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center
Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association, and Tennessee Medical Association
Disclosure: Lilly Consulting fee Consulting; Astellas Consulting fee Speaking and teaching; Indevus Consulting fee Speaking and teaching

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Shlomo Raz, MD, Professor, Department of Surgery, Division of Urology, University of California at Los Angeles School of Medicine
Shlomo Raz, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, and California Medical Association
Disclosure: Nothing to disclose.

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Gyrus-ACMI Honoraria Speaking and teaching

Chief Editor

Bradley Fields Schwartz, DO, FACS, Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine
Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.